SCHEMBL838439

SCHEMBL838439

Cc1ccccc1-n1nnc2c(Cl)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.43
PI4K2B Q8TCG2 1/20 0.43
PI4K2A Q9BTU6 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
LMNA P02545 4/20 0.41
TP53 P04637 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 6/20 0.41
TSHR P16473 2/20 0.41
SLC2A1 P11166 2/20 0.39
SLC2A2 P11168 2/20 0.39
SLC2A3 P11169 2/20 0.39
HTT P42858 3/20 0.37
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839577 0.85 ALDH1A1 (0.39) LMNATP53SMN1; SMN2MAPK1ALDH1A1
SCHEMBL4928544 0.78 ALDH1A1 (0.56) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL839657 0.73 SLC2A1 (0.54) LMNATP53SMN1; SMN2ALDH1A1TSHR
SCHEMBL9476934 0.73 ALDH1A1 (0.53) LMNATP53SMN1; SMN2MAPK1ALDH1A1
SCHEMBL2732314 0.72 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL21138500 0.72 POLB (0.39) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL4928331 0.69 TP53 (0.49) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL1244897 0.68 GPR119 (0.48) LMNASMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL4922738 0.67 ALDH1A1 (0.64) LMNAALDH1A1TSHRHTTHPGD
SCHEMBL21138789 0.67 ALDH1A1 (0.40) LMNAALDH1A1SLC2A1SLC2A2SLC2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 PI4KA 486/4885PI4K2B 578/4885PI4K2A 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.